Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2380 Conejo Spectrum St, Suite 200 THOUSAND OAKS CA 91320 |
Tel: | 1-805-3959669 |
Website: | https://www.atarabio.com |
IR: | See website |
Key People | ||
Pascal Touchon President, Chief Executive Officer, Director | Eric Hyllengren Chief Financial Officer, Senior Vice President, Investor Relations and Finance | K. Amar Murugan Executive Vice President, Chief Legal Officer |
Business Overview |
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company's T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform. |
Financial Overview |
For the fiscal year ended 31 December 2023, Atara Biotherapeutics Inc revenues decreased 87% to $8.6M. Net loss increased 21% to $276.1M. Revenues reflect License and collaboration revenue decrease of 99% to $687K. Higher net loss reflects Gain on sale of ATOM facility decrease from $50.2M (income) to $0K, Restructuring Charges & Provisions increase from $2.5M to $5.6M (expense). |
Employees: | 225 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $69.61M as of Dec 31, 2023 |
Annual revenue (TTM): | $8.57M as of Dec 31, 2023 |
EBITDA (TTM): | -$264.45M as of Dec 31, 2023 |
Net annual income (TTM): | -$276.13M as of Dec 31, 2023 |
Free cash flow (TTM): | -$194.20M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 119,359,230 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |